학술논문

CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): An open-label dose-finding and first-in-human study

Document Type

Article

Author

Naing, A.; Thistlethwaite, F.; De Vries, E.G.E.; Eskens, F.A.L.M.; Uboha, N.; Ott, P.A.; Lorusso, P.; Garcia-Corbacho, J.; Boni, V.; Bendell, J.; Autio, K.A.; Randhawa, M.; Durm, G.; Gil-Martin, M.; Stroh, M.; Hannah, A.L.; Arkenau, H.-T.; Spira, A.

Source

In: Journal for ImmunoTherapy of Cancer. (Journal for ImmunoTherapy of Cancer, 23 July 2021, 9(7))

Subject

Language

English

ISSN

20511426

Online Access

Full Text (ProQuest Central) Open Access (EBSCO) Web of Science JCR 저널정보 Scopus Find it@PNU

이메일

부산대학교 도서관

Online Access

메일 발송